Taiwanese doctor highlights 'skinny needle' drug's heart benefits beyond weight loss
Translated from Chinese, summarized and contextualized by DistantNews.
At a glance
- The popular "skinny needle" (GLP-1 receptor agonist) used for weight loss also shows promise in protecting cardiovascular health, according to a doctor.
- While originally for type 2 diabetes, these drugs mimic natural hormones to increase satiety, control blood sugar, and aid weight management.
- International studies suggest GLP-1 drugs can reduce the risk of heart attack, stroke, and cardiovascular death, even in patients without diabetes but with obesity and heart conditions.
Beyond its widespread use for weight loss, the "skinny needle," medically known as a GLP-1 receptor agonist, is emerging as a significant tool for protecting cardiovascular health, according to a physician in Kaohsiung.
Many patients think that having a stent means their heart disease has been cured. In fact, the stent only opens up blocked blood vessels; the atherosclerosis that causes the disease may continue to progress.
Dr. Wu Yiting, a cardiologist at Kaohsiung Municipal United Hospital, explained that while stents open blocked arteries, the underlying atherosclerosis can continue to progress. Effective management of blood pressure, blood sugar, blood lipids, and weight remains crucial to prevent major cardiovascular events like heart attacks and strokes. The GLP-1 receptor agonists, initially developed for type 2 diabetes, work by mimicking natural hormones to enhance feelings of fullness, slow stomach emptying, and consequently help control blood sugar and weight.
The reason why GLP-1 drugs have received much attention from the medical community in recent years is not only their good weight loss effect, but also that multiple large international studies have found that they can reduce the risk of myocardial infarction, stroke, and cardiovascular death.
Dr. Wu highlighted that recent international research has underscored the cardiovascular benefits of these drugs. A notable study published in The New England Journal of Medicine in 2023, the SELECT trial, demonstrated that GLP-1 receptor agonists effectively lowered the incidence of major cardiovascular events in obese patients with cardiovascular disease, even if they did not have diabetes. The drugs are thought to offer benefits beyond weight and glucose control, potentially including anti-inflammatory effects, improved vascular function, and better blood pressure and lipid profiles.
This right shall not be denied except on narrow grounds expressly provided by law, with reasons recorded.
However, Dr. Wu cautioned that these "skinny needles" are not suitable for everyone. Common side effects include nausea, bloating, and gastrointestinal discomfort. As prescription medications, they require a thorough professional assessment by a physician based on an individual's health status, medical history, and risk factors. He emphasized that consistent medication, a healthy diet, and regular exercise are essential for effectively reducing the risk of cardiovascular disease recurrence.
However, Dr. Wu reminded that skinny needles are not suitable for everyone.
Originally published by Liberty Times in Chinese. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.